Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study

Author:

Kittai Adam S.1ORCID,Bond David1ORCID,Huang Ying1,Bhat Seema A.1,Blyth Emily2ORCID,Byrd John C.3ORCID,Chavez Julio C.4ORCID,Davids Matthew S.5ORCID,Dela Cruz Jamie P.5,Dowling Mark R.67,Duffy Caitlyn5ORCID,Ho Carrie8ORCID,Jacobson Caron5ORCID,Jaglowski Samantha1,Jain Nitin9ORCID,Lin Kevin H.5ORCID,Miller Cecelia10,McCarthy Christine11,Omer Zulfa3ORCID,Parry Erin5ORCID,Rai Manoj12ORCID,Rogers Kerry A.1ORCID,Saha Aditi4ORCID,Schachter Levanto12ORCID,Scott Hamish6ORCID,Senapati Jayastu9ORCID,Shadman Mazyar7ORCID,Siddiqi Tanya13ORCID,Stephens Deborah M.14ORCID,Vanguru Vinay15,Wierda William9ORCID,Woyach Jennifer A.1ORCID,Thompson Philip A.67

Affiliation:

1. Division of Hematology, The Ohio State University, Columbus, OH

2. Blood Transplant and Cell Therapies Program, Westmead Hospital Department of Haematology, Westmead, NSW, Australia

3. Department of Internal Medicine, University of Cincinnati, Cincinnati, OH

4. Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

5. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

6. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia

7. Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Melbourne, Australia

8. Clinical Research Division, Fred Hutchinson Cancer Center and University of Washington, Seattle, WA

9. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

10. Department of Pathology, The Ohio State University, Columbus, OH

11. Department of Hematology, Department of Clinical Informatics, City of Hope National Medical Center, Duarte, CA

12. Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR

13. Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA

14. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

15. Institute of Haematology, Royal Prince Alfred Hospital, NSW, Australia

Abstract

PURPOSE Outcomes for Richter transformation (RT) are poor with current therapies. The efficacy and safety of anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) for RT are not established. METHODS We performed an international multicenter retrospective study of patients with RT who received CAR-T. Patient, disease, and treatment characteristics were summarized using descriptive statistics, and modeling analyses were used to determine association with progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated from the date of CAR-T infusion. RESULTS Sixty-nine patients were identified. The median age at CAR-T infusion was 64 years (range, 27-80). Patients had a median of four (range, 1-15) previous lines of therapy for CLL and/or RT, including previous Bruton tyrosine kinase inhibitor and/or BCL2 inhibitor therapy in 58 (84%) patients. The CAR-T product administered was axicabtagene ciloleucel in 44 patients (64%), tisagenlecleucel in 17 patients (25%), lisocabtagene maraleucel in seven patients (10%), and brexucabtagene autoleucel in one patient (1%). Eleven patients (16%) and 25 patients (37%) experienced grade ≥3 cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, respectively. The overall response rate was 63%, with 46% attaining a complete response (CR). After a median follow-up of 24 months, the median PFS was 4.7 months (95% CI, 2.0 to 6.9); the 2-year PFS was 29% (95% CI, 18 to 41). The median OS was 8.5 months (95% CI, 5.1 to 25.4); the 2-year OS was 38% (95% CI, 26 to 50). The median duration of response was 27.6 months (95% CI, 14.5 to not reached) for patients achieving CR. CONCLUSION CAR-T demonstrates clinical efficacy for patients with RT.

Publisher

American Society of Clinical Oncology (ASCO)

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3